title: A case of Vogt-Koyanagi-Harada disease with good visual acuity in spite of subfoveal fold.
abstract: BACKGROUND
  Vogt-Koyanagi-Harada (VKH) disease patients with the complication of subretinal pigmented proliferative tissue tend to have a poor visual prognosis.
  
  
  METHODS
  We herein report a case of VKH with good visual acuity despite a prominent subretinal fold.
  
  
  METHODS
  A 24-year-old woman, who experienced several recurrent episodes of VKH disease, had bilateral serous retinal detachment with poor vision (RE 20/40 and LE 20/25). After the administration of high doses of systemic corticosteroids and D-mannitol, the subretinal fluid disappeared and the sensory retinas gradually became reattached. During the course of therapy, prominent pigmented subretinal strands were formed in both eyes. Optical coherence tomography disclosed that the strands existed at the retinal pigment epithelium level. Amazingly, we observed a change in the location of the fold in the posterior retina during the course of the disease. The patient finally showed the "sunset glow" fundi and a subretinal fold that was located almost directly beneath both fovea. Fortunately, this patient was able to recover and finally achieve a good visual acuity (RE 20/17 and LE 20/17).
  
  
  CONCLUSIONS
  We reported a VKH disease patient with a good visual acuity despite a remarkable subfoveal fold, which changed its location during the course of the disease.
authors.affiliation: Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Noda
authors.forename: Koh Hei
authors.initials: KH
authors.lastname: Sonoda
authors.forename: Takehiko
authors.initials: T
authors.lastname: Nakamura
authors.forename: Yoh Ichi
authors.initials: YI
authors.lastname: Kawano
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Ishibashi
authors.forename: Hajime
authors.initials: H
authors.lastname: Inomata
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D005654:Fundus Oculi; D006801:Humans; D008353:Mannitol / Q000009:adverse effects*; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000473:pathology; D014463:Ultrasonography; D014607:Uveomeningoencephalitic Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D014792:Visual Acuity
chemical_list: D000305:Adrenal Cortex Hormones; D008353:Mannitol